Sanchine三精品牌怎么样 申请店铺

我要投票 Sanchine三精在补钙行业中的票数:430 更新时间:2025-07-07
Sanchine三精是哪个国家的品牌?「Sanchine三精」是 哈药集团三精制药有限公司 旗下著名品牌。该品牌发源于黑龙江,由创始人芦传有在2015期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力Sanchine三精品牌出海!将品牌入驻外推网,定制Sanchine三精品牌推广信息,可以显著提高Sanchine三精产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

Sanchine三精怎么样

三精制药始建于1950年,初期以生产肌肉和静脉水针剂为主,是黑龙江省最早的专业化生产水针剂和国内最早引进国外水针剂一连机生产设备的企业,是最早通过国家GMP认证的医药企业之一。公司现总占地面积110万平方米,员工总数近6000人,是以OTC产品、处方药与保健食品为主、医药原料和制剂并重的综合性制药企业。2004年,“三精”品牌被国家工商总局认定为“驰名保护”。2011年5月13日,“三精”品牌在“2011中国最有价值品牌评价”中,经权威机构认定,品牌价值为68.93亿元人民币。

目前,三精制药拥有下属子公司15家,其中工业子公司8家、商业子公司5家、其他相关产业子公司2家。截至目前,公司口服液、口服溶液剂、小容量注射剂(非最终灭菌)、冻干粉针剂、片剂、粉针剂、胶囊剂、颗粒剂、合剂、糖浆剂、洗剂、茶剂、散剂13个剂型及无菌原料药(磷霉素钠、炎琥宁)、原料药(拉西地平、盐酸罗沙替丁醋酸酯)均通过2010版GMP认证。其中,口服液剂型产品年生产能力达16亿支。公司主导产品包括葡萄糖酸钙口服溶液、葡萄糖酸锌口服液、双黄连口服液、司乐平片等。近年来,通过药品、保健品的新产品立项研发,不断完善产品线,丰富产品阵容。

六十余年的制药经验,先进的技术设备,一流的管理手段,完善的科研开发体系,使“三精”牌在国内外丰享盛誉。三精一直将产品和服务视为核心竞争力,同时高度重视产品的研发,2004年建成较具规模的研发中心,已成为黑龙江省药物制剂工程技术研究中心、黑龙江省西药制剂重点实验室,承担“十一五”“重大新药创制”科技重大专项——“新型口服缓控释制剂及工艺技术平台”课题和“十二五”“重大新药创制”科技重大专项——“抗阿尔茨海默病药重酒石酸卡巴拉汀及其胶囊的研究开发”课题。2008年,公司成为“国家首批创新型企业”,2012年入选国家火炬计划重点高新技术企业。公司还先后荣获了全国质量管理先进企业、全国守合同重信用企业、全国医药系统优秀企业、全国“五·一劳动奖状”先进集体、“全国企业文化优秀成果奖”、“全国医药行业药品质量诚信建设示范企业”、“21315国际质量信用AAA++级”、“中国优秀诚信企业”、“中国化学制药行业工业企业综合实力百强”企业、黑龙江省“科技创新优秀企业奖”等荣誉称号。

Sanjing pharmaceutical was founded in 1950. At the early stage, it mainly produces muscle and intravenous water injection. It is the first professional enterprise in Heilongjiang Province to produce water injection and the first enterprise in China to introduce foreign water injection production equipment. It is also one of the first pharmaceutical enterprises to pass the national GMP certification. The company now covers an area of 1.1 million square meters and employs nearly 6000 people. It is a comprehensive pharmaceutical enterprise focusing on OTC products, prescription drugs and health food, with equal emphasis on pharmaceutical raw materials and preparations. In 2004, "three fine" brand was recognized as "well-known protection" by the State Administration for Industry and commerce. On May 13, 2011, in the "2011 China's most valuable brand evaluation", the brand value of "three fine" was recognized by the authority as RMB 6.893 billion. At present, Sanjing pharmaceutical has 15 subsidiaries, including 8 Industrial subsidiaries, 5 Commercial subsidiaries and 2 other related industrial subsidiaries. Up to now, 13 dosage forms of the company's oral liquid, oral solution, small volume injection (non final sterilization), freeze-dried powder injection, tablet, powder injection, capsule, granule, mixture, syrup, lotion, tea, powder, sterile API (fosfomycin sodium, Yanhuning), API (lacidipine, rosattidine hydrochloride acetate) have passed GMP certification of 2010 version. Among them, the annual production capacity of oral liquid dosage products reached 1.6 billion. The company's leading products include calcium gluconate oral solution, zinc gluconate oral solution, Shuanghuanglian oral solution, and silepin tablets. In recent years, through the research and development of new products of drugs and health products, the product line has been continuously improved and the product lineup has been enriched. With more than 60 years of pharmaceutical experience, advanced technology and equipment, first-class management means, and perfect scientific research and development system, the "three refined" brand enjoys a good reputation at home and abroad. Sanjing has always regarded products and services as its core competitiveness, and attached great importance to product research and development. In 2004, it established a relatively large-scale research and development center, which has become Heilongjiang pharmaceutical engineering and technology research center and Heilongjiang western pharmaceutical Key Laboratory, undertaking the major science and technology project of "11th Five Year plan" and "major new drug creation" -- new oral sustained and controlled release preparations and technology "Platform" project and "12th Five Year Plan" science and technology major project of "major new drug creation" - research and development of anti Alzheimer's disease drug kabalatin tartrate and its capsule ". In 2008, the company became "the first batch of national innovative enterprises", and in 2012, it was selected as a key high-tech enterprise in the national torch plan. The company has also won the national advanced quality management enterprise, the national contract abiding and trustworthy enterprise, the national excellent pharmaceutical system enterprise, the national advanced collective of "May 1st Labor Award", "national enterprise culture excellent achievement award", "national pharmaceutical industry pharmaceutical quality and integrity construction demonstration enterprise", "21315 International quality and credit AAA + + level", "China excellent and integrity enterprise" "Top 100 enterprises with comprehensive strength in China's chemical and pharmaceutical industry" and "science and technology innovation excellent enterprise award" of Heilongjiang Province, etc.

本文链接: https://brand.waitui.com/41c6b1011.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

欧盟推迟与中国签署气候行动联合声明,外交部回应

7月7日,外交部发言人毛宁主持例行记者会。路透社记者提问,英国《金融时报》报道,欧盟推迟了本月与中国签署气候行动联合声明的计划。报道称,欧盟表示,除非中国承诺加大力度削减温室气体排放,否则欧盟不会希望这份联合声明提前签署。中欧将在本月举行峰会,中国是否也在考虑做出更多气候承诺?毛宁表示,具体的问题建议你向中方的主管部门询问。我可以告诉你的是,中国始终积极推进绿色低碳发展。过去10年,中国的非化石能源占能源消费总量的比重增加至17.9%,碳排放强度下降了超过34%。我们将继续同各国一道加强应对气候变化的国际合作,为绿色转型和人类的可持续发展作出贡献。(澎湃)

43分钟前

机构:今年以来全球新船订单总量同比下降54%

据克拉克森研究统计,年初至今全球新船订单总量同比下降54%。克拉克森新造船价格指数同比下滑1%。集装箱船(新船订单量达到190万标准箱)、邮轮和渡轮新造船市场依然保持活跃;而气体船和油轮新造船投资放缓。新船交付保持稳定,中国船厂占比达到48%、韩国占31%、日本占13%;不过中国船厂新船订单份额有所下滑,从2024年的70%降至52%。(证券时报)

43分钟前

中国动力:预计上半年净利润同比增长68.28%到141.90%

36氪获悉,中国动力公告,预计2025年半年度实现归属于母公司所有者的净利润80000万元到115000万元,同比增加68.28%到141.90%。业绩预增的主要原因是船舶行业增长,公司柴油机板块销售规模扩大,合同结算增加,产品价格增长以及毛利率提升。

43分钟前

皖维高新:上半年净利润同比预增81.34%—104.48%

36氪获悉,皖维高新公告,预计2025年半年度公司实现净利润为2.35亿元—2.65亿元,同比增长81.34%—104.48%。报告期内,行业下游市场逐步回暖,客户需求有所提升,公司主产品聚乙烯醇(PVA)、醋酸乙烯、醋酸甲酯的销量同比增长。其中,PVA实现了销量和价格的双增长。

43分钟前

印尼首席谈判代表将于周一访问美国,以赶在关税截止日期前完成谈判

印尼经济事务协调部发言人哈里奥·利曼塞托表示,该国在美关税谈判的主要代表、高级经济部长阿里朗加·哈拉托计划于周一前往美国。阿里朗加目前正陪同总统普拉博沃·苏比安托参加金砖国家会议,之后他将前往美国监督关税谈判,以确保在 7 月 9 日的截止日期前完成谈判,该日期已临近。(新浪财经)

43分钟前

本页详细列出关于Sanchine三精的品牌信息,含品牌所属公司介绍,Sanchine三精所处行业的品牌地位及优势。
咨询